CEO Greg Mayes (Antios)

The hunt for a hep B cure heats up, as An­tios Ther­a­peu­tics preps for an IPO

While he­pati­tis B virus (HBV) in­fec­tion is avoid­able with a vac­cine, a host of com­pa­nies are search­ing for a cure for the hun­dreds of thou­sands in the US who al­ready have it. An­tios Ther­a­peu­tics threw its hat in the ring three years ago, and on Mon­day closed a $96 mil­lion crossover round to see its lead pro­gram through Phase II.

When asked if an IPO is on the hori­zon, CEO Greg Mayes said: “We’re go­ing to be pre­pared for one, yes.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.